Purpose Salivary duct carcinoma (SDC) is an aggressive salivary malignancy which is resistant to chemotherapy and has high mortality rates. We investigated the molecular landscape of SDC, focusing on genetic alterations and gene expression profiles.
4 has relevance for emerging clinical studies of ADT and other targeted therapies in SDC. The similarities between SDC and apocrine breast cancer indicate that clinical data in breast cancer may generate useful hypotheses for SDC.
Translational relevance
Salivary duct carcinomas (SDCs) often present with locoregionally advanced disease or distant metastases. The majority of patients ultimately succumb to treatment-resistant disease. Therapies such as androgen-deprivation therapy (ADT) and HER2 inhibition have achieved anecdotal responses, but the rarity of this disease and limited molecular data have impeded the design of rational clinical studies. To date, molecular profiling of SDCs has been restricted to ad hoc analyses of only specific genes. Here, through whole-exome, targeted capture and transcriptome sequencing, we identified many targetable alterations, as well as potential ADT resistance mechanisms. Our analysis also reveals a strong molecular similarity to apocrine breast carcinoma, a tumor type in which ADT has demonstrated activity. Taken together, these data expand our knowledge of the biology of SDC, particularly molecular features that have relevance to ADT, HER2 inhibition, and other targeted therapies.
Introduction
Salivary duct carcinoma (SDC) is one of the most aggressive head and neck tumors, accounting for 2% of salivary gland cancers. The majority of cases originate in the parotid or submandibular gland, with lymph node metastasis and facial nerve palsy common at diagnosis (1, 2) . Standard treatment includes surgical resection with or without adjuvant radiotherapy, but local disease recurrence and distant metastasis are common and rarely responsive to chemotherapy. Therefore, the overall prognosis remains poor with a long-term survival of 30-55% (1-3).
SDCs may arise de novo or develop as the malignant component of a carcinoma ex pleomorphic adenoma (denoted SDC ex-PA), which is a cancer that has transformed from a longstanding pleomorphic adenoma.
Histological findings include a hyalinized, fibrous stroma infiltrated by neoplastic ducts, which resembles the morphology of invasive ductal carcinoma of the breast (4) . SDC and breast cancer also share several immunohistochemistry (IHC) characteristics including positive staining for the androgen receptor (AR), which is detected in a majority of both tumor types (3, (5) (6) (7) . Several case series have reported clinical benefit from androgen-deprivation therapy (ADT), which has been suggested as potential first-line therapy in patients with recurrent AR-positive SDC (8, 9) . Amplification of ERBB2 (also known as human epidermal growth factor receptor 2, HER2) has been detected in approximately one-third of SDCs, and is associated with poor prognosis (3, 5, 10, 11) . The ERBB2 inhibitor trastuzumab has been tested with reported cases of clinical response (12) (13) (14) , although no controlled study has been performed. It has been proposed that SDC, analogous to breast cancer, can be divided into different subtypes based on receptor status: AR-positive, ERBB2-positive, and basal-like (AR-and ERBB2-negative) phenotypes (6) . However, this hypothesis is based on immunohistochemical data only, and it is unclear whether SDC resembles breast cancer on a broader molecular level.
Previous genetic studies of SDC have focused on a limited number of genes, and have found TP53 (5, 15) . To date, no unbiased comprehensive molecular characterization of SDC with whole exome or transcriptome sequencing has been reported.
In this study, we performed whole exome sequencing of tumor and matched normal DNA as well as tumor RNA sequencing, and analyzed the spectrum of genetic alterations in 16 SDC patients. In order to classify SDC in comparison to breast cancer, global gene expression was analyzed and compared to published datasets of breast carcinoma. For additional comparison, we also analyzed targeted sequencing data in a second cohort of 15 recurrent/metastatic SDCs that were profiled as part of an institutional precision medicine platform. We report a high frequency of potentially actionable genetic alterations in this rare, often lethal cancer. Taken together, this is the first comprehensive genetic study of SDC, providing a molecular foundation for future research and clinical trials.
Materials and methods

Case selection
With written informed consent and following Institutional Review Board (IRB) approval, tumor and matched normal (peripheral blood or non-neoplastic normal tissue) specimens were obtained from SDC patients treated at Memorial Sloan Kettering Cancer Center during the years 2000 to 2015. For cohort 1 (denoted SDC1-SDC16), tissue samples were snap frozen in liquid nitrogen at the time of surgery and stored at -80 °C. Hematoxylin and eosin stained tumor sections were independently re-evaluated by a head and neck pathologist (N.K.) confirming the SDC diagnosis. Sixteen cases with sufficient tumor material were subjected to whole exome sequencing of tumor and normal DNA as well as tumor RNA sequencing.
For cohort 2 (denoted SDC17-SDC31), tumors were sequenced using a clinical next-generation sequencing platform, Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer 7 Targets (MSK-IMPACT) (16) . These were patients with advanced (all recurrent or metastatic) cancers who were offered targeted tumor sequencing in the context of an IRB-approved study (NCT01775072).
For these cases, tumor DNA and matched normal blood DNA were subjected to massively parallel sequencing targeting the exons of 410 selected genes and selected intronic and regulatory regions (listed in Supplementary Table 1) , with technical details of this assay previously described (16) .
DNA and RNA extraction
DNA was extracted from fresh frozen tissue or whole blood using the DNeasy Blood and Tissue Kit (Qiagen), and quantified with the PicoGreen assay (Thermo Fisher Scientific). RNA was extracted using the RNeasy Mini kit (Qiagen), and quantified with the RiboGreen assay (Thermo Fisher Scientific). DNA and RNA quality and integrity was analyzed by BioAnalyzer (Agilent Technologies) and Fragment Analyzer (Advanced Analytics).
Whole exome library preparation and sequencing
Whole exome sequencing libraries were prepared using the SureSelect XT library preparation kit (Agilent). DNA was sheared using a LE220 Focus Ultra-sonicator (Covaris), and the fragments were endrepaired, adenylated, ligated to Illumina sequencing adapters, and amplified by PCR. Exome capture was performed using the SureSelect XT v4 51Mb capture probe set (Agilent) and captured exome libraries were enriched by PCR. Final libraries were quantified using the KAPA Library Quantification Kit (KAPA Biosystems), Qubit Fluorometer (Life Technologies) and 2100 BioAnalyzer (Agilent), and were sequenced on a HiSeq2500 sequencer (Illumina) using 2 x 125bp cycles.
RNA library preparation and sequencing
RNA sequencing libraries were prepared using the KAPA Stranded RNA-Seq with RiboErase sample preparation kit (KAPA Biosystems). Total RNA (100ng) was ribosomal RNA-depleted and fragmented, followed by first and second strand synthesis, A tailing, adapter ligation and PCR amplification (using 11
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Mutation analysis
The match between tumor and normal samples of each patient was confirmed with fingerprinting analysis using an in-house panel of 118 single nucleotide-polymorphisms, and with VerifyBamID (17) . Raw sequencing data were aligned to the hg19 genome build using the Burrows-Wheeler Aligner (BWA) version 0.7.10 (18). Indel realignment, base quality score recalibration and removal of duplicate reads were performed using the Genome Analysis Toolkit (GATK) version 3.2.2 (broadinstitute.org/gatk), following guidelines for raw read alignment (19 
Validation of mutations
All potential indels and low-confidence SNVs, a random selection (15%) of the high-confidence SNVs, and the TERT gene promoter were subjected to orthogonal validation using NimbleGen SeqCap EZ target enrichment (Roche), using 500x and 250x sequencing depth for tumor and normal DNA, respectively.
Variants with >100x of tumor and normal DNA coverage, >15% variant allelic fraction in tumor, and <3% variant allelic fraction in normal DNA, were considered validated. The overall validation rate in high-confidence SNVs was 96.2%. Validated indels and low confidence SNVs, as well as all highconfidence SNVs, were included in subsequent analyses.
Copy number analysis and tumor purity estimation
Allele-specific copy number data was acquired by analysis of whole exome sequencing bam files using OncoSNP-SEQ (sites.google.com/site/oncosnpseq). Chromosome arm-level alterations and statistically significant amplifications and deletions were determined and visualized using GISTIC 2.0 (broadinstitute.org/cancer/cga/gistic). To determine tumor purity, we analyzed RNA sequencing data using the ESTIMATE algorithm (20) .
Gene expression analysis
For SDC samples, raw FASTQ files were aligned to the hg19 genome using STAR aligner with default parameters (21) . Aligned fragments were counted with Rsamtools v3.2 and annotated using the TxDb.Hsapiens.UCSC.hg19.knownGene version 3.2 transcript database. The raw count matrix for 591 PAM50-annotated breast cancers published by The Cancer Genome Atlas (TCGA) (22) 
Immunohistochemical analysis
Sections of formalin-fixed, paraffin embedded tumor tissue were stained with androgen receptor antibody clone AR-441 (monoclonal mouse, dilution 1:100; Dako), and were considered positive if immunoreactivity was detected in ≥5% of tumor cell nuclei. ERBB2 staining was done using the anti-HER-2/neu antibody, clone 4B5 (monoclonal rabbit; Roche), and were visualized using the Ultra View Universal DAB detection kit (Ventana Medical Systems). S100 was detected using antibody GA504 (polyclonal rabbit, dilution 1:8000; Dako).
Fluorescence in-situ hybridization (FISH)
Formalin-Fixed Paraffin-Embedded (FFPE) tissue samples were tested for NTRK3 rearrangements by a break-apart FISH assay using a commercial NTRK3 break-apart FISH probe (Empire Genomics). Fourmicron (4 μm) FFPE tissue sections generated from FFPE blocks of tumor specimens were pretreated by deparaffinizing in xylene and dehydrating in ethanol. Dual-color FISH assay was conducted according to the protocol for FFPE sections from Vysis/Abbott Molecular with a few modifications. FISH analysis and signal capture were conducted on a fluorescence microscope (Zeiss) coupled with ISIS FISH Imaging System (Metasystems). We analyzed 100 interphase nuclei from each tumor specimen. 
Detection of AR-V7
The AR locus of the RNA sequencing data was displayed with Sashimi plots in IGV 2.3. A sample was reported as androgen receptor splice variant 7 (AR-V7) positive if at least two uniquely aligned junction reads spanning exon 3 and the downstream cryptic exon (expressed intronic region CE3) were detected, with a minimum of 5 nucleotide overhang on either side without mismatches. The number of reads spanning AR-V7 variant splice junctions was normalized to the total number of reads aligned to the reference transcriptome.
PCR analyses
For validation of fusion genes and expression of the AR-V7 splice variant, cDNA was synthesized from tumor RNA using Superscript III Reverse Transcriptase (ThermoFisher Scientific), amplified by PCR and visualized on a 1.5% agarose gel. For validation of fusion genes with intronic breakpoints, PCR was performed using tumor genomic DNA. All primer sequences are listed in Supplementary Table 2 .
Androgen receptor signaling analysis
To generate an androgen receptor signaling index, we calculated the average z-score of 46 canonical target genes that are up-regulated by the androgen receptor (Human Androgen Receptor Signaling Targets PCR Array, Qiagen), calculated from FPKM data.
Results and Discussion
Genetic landscape of salivary duct carcinoma
To investigate the spectrum of somatic genetic alterations in SDC, we performed whole-exome sequencing of snap-frozen tumor and matched normal DNA from 16 patients (see Table 1 Figure 1) . We also performed RNA sequencing, with an average of 170M total reads, of which 88% were aligned to the mapping sequence with high quality (Supplementary Figure 2) . Orthogonal resequencing showed a high validation rate (>96%) of the mutations detected, and only high confidence and/ or validated mutations were included in subsequent analyses (see methods). The average estimated tumor purity was 68% (range: 52-93%), which is higher than reported for most tumor types including breast cancer (20) .
We detected a median of 50 non-silent somatic mutations per tumor, corresponding to approximately 1.7 mutations per megabase ( Figure 1 and Supplementary Table 3 ). This places the mutational load of SDC in the lower one-third of solid tumors, close to breast cancer as well as pancreas, prostate, and kidney cancers (24) . This mutational burden is higher than that of adenoid cystic carcinoma of the salivary gland, which has 0.3 mutations per megabase (25) . In total, 86% were missense mutations, 12% truncating mutations, 2% splice site mutations, and 0.6% in-frame indels. RNA sequencing detected 50% of all mutations, but 94% of mutations in the COSMIC database occurring in cancer genes (Supplementary Figure 3A) . The latter group mostly contained mutations with evidence supporting likely importance as drivers of oncogenesis, suggesting that such alterations may be commonly expressed and detected by RNA sequencing. The variant allele frequencies in this group of mutations were higher in RNA than in DNA (Supplementary Figure 3B) , which is in line with a previous study (26) , and supports the hypothesis that many transforming mutations are highly expressed in tumor cells.
Copy number alterations
We noted a relatively low rate of copy number alterations (CNAs), with amplifications or deletions on chromosome arm-level occurring in 5 patients. The only recurrent arm-level CNA was 8q amplification, present in 3 of 16 (19%) patients (Figure 1 ), which is in line with previous findings in estrogen receptornegative breast cancer and head and neck squamous cell carcinoma (22, 27 several tumor types including prostate cancer (28) , and PLAG1, which is rearranged and overexpressed in a majority of pleomorphic adenomas (29) . Significant focal amplifications included loci 17q12 (including ERBB2) and 10q11.21 (including RET) in 4 and 1 of 11 patients, respectively (Supplementary Figure 4) .
Fusion genes
Unique fusion genes were detected in 5 of 16 patients using RNA sequencing, and were all confirmed by PCR analysis (Figure 1, Supplementary Figure 5) . One patient had an ETV6-NTRK3 fusion, which is found in a majority of mammary analogue secretary carcinoma (MASC) tumors (30) . The fusion gene included ETV6 exons 1-4 and NTRK3 exons 14-20, which is different from the most common fusion variant (where the breakpoints are located in ETV6 exon 5 and NTRK3 exon 15), but has been previously reported in MASC (31) . FISH analysis showed rearrangement of the NTRK3 locus in 92% of the cells (Supplementary Figure 6D) . To confirm the SDC diagnosis, we re-reviewed additional tissue sections and noted typical SDC morphology (Supplementary Figure 6A-C) , which is distinct from that of MASC (32) . Two patients with SDC ex-PA had CTNNB1-PLAG1 or LIFR-PLAG1 fusions, which have been previously described in pleomorphic adenoma (30) . Another patient had a BCL6-TRADD fusion gene.
BCL6 is commonly translocated in diffuse large B cell lymphoma (35) , but has never been reported with TRADD as fusion partner. Finally, one tumor harbored an ABL1-PPP2R2C fusion. Rearrangements including the 3' portion of ABL1 with several different 5' fusion partners are found in hematological malignancies (36) . However, the reciprocal PPP2R2C-ABL1 fusion was not detected by RT-PCR.
Recurrent genetic alterations
Recurrent mutations and CNAs are depicted in Figure 1A . We interrogated selected genes in a second cohort, consisting of 15 patients with recurrent or metastatic SDC, whose tumors were analyzed using MSK-IMPACT, a clinical sequencing assay designed to detect potentially targetable mutations and copy number alterations in 410 cancer-related genes (Supplementary Figure 7A and Supplementary Table 4 for results, and Supplementary Table 5 for clinical information) (16) . Overall, SDC showed a relatively low number of mutations and CNAs compared to other tumor types that were analyzed using the same platform (Supplementary Figure 7B) , which is in line with our findings in cohort 1.
Across both cohorts (n=31), TP53 alterations were most prevalent and were detected in 17 (55%) cases ( Figure 1B) . The frequency of TP53 alterations was higher in cohort 2 than in cohort 1 (80% vs 31%, OR=8.8, P=0.011; Fisher's exact test), suggesting that this mutation may be enriched in tumors that behave aggressively, since all cohort 2 tumors were recurrent/metastatic.
Amplification of ERBB2 was detected in 10 of 31 (32%) cases, which is similar to previous SDC studies (3, 5, 10, 11) . The ERBB2 inhibitor trastuzumab is used as standard treatment of ERBB2 amplified breast cancer (37) , and has been tested with promising results in SDC (12) (13) (14) . In our study, 3 patients with ERBB2 amplification were treated with trastuzumab in combination with chemotherapy. One patient received trastuzumab for 1 year as part of adjuvant therapy and had no sign of disease at follow-up 6 years later, one was alive with stable bone metastases after receiving trastuzumab as maintenance This indicates that ERBB2 amplification and MAPK pathway activation are the predominating drivers of oncogenesis in SDC, and may act through independent or redundant mechanisms.
Seven of 31 (23%) patients harbored activating HRAS mutations. Interestingly, 3 of 3 patients with an
HRAS G13R mutation also had a co-occurring PIK3CA H1047R mutation. On the other hand, no PIK3CA mutation was detected in the 4 patients with HRAS Q61R (p=.029; Supplementary Table 6 ). These data suggest that HRAS Q61R might be a more potently activating mutation, whereas HRAS G13R cooperates with PIK3CA H1047R to promote oncogenesis in SDC. Similar findings have been observed in other cancer types, where PIK3CA has been shown to cooperate with specific RAS mutations (39), in a manner that can generate dependency on PI3K signalling and resistance to ERBB2 inhibition. These data may have relevance for the targeting of PIK3CA or ERBB2 in SDC.
Mutations in the promoter region of the human telomerase reverse transcriptase (TERT) gene occur in several cancer types (40) . We sequenced the TERT promoter and found no mutations in any of 31 tumors, suggesting that these alterations are rare in SDC.
In total, 21 of 31 (70%) patients had a history of tobacco smoking. There were no associations between smoking status and any genetic alterations detected in the study. There were also no significant associations between the above-described genetic alterations and overall or recurrence-free survival (data not shown).
Actionability of alterations
To investigate the clinical relevance of molecular characterization in SDC patients, we categorized alterations according to levels of evidence supporting standard or investigative therapies. There were no alterations that have standard of care therapeutic implications, since there are no FDA-approved drugs or biomarkers in SDC. However, 19 tumors (61%) had alterations that were potentially actionable, because the specific alteration corresponded to either an FDA-approved treatment, or to a treatment with published clinical evidence in another cancer type. An additional 3 tumors (10%) contained alterations in which preclinical studies suggest potential activity of such drugs ( Figure 1C and Supplementary Table 7) .
Taken together, a high percentage of SDCs have actionable alterations with supportive clinical evidence.
These findings are in stark contrast to the two other salivary cancer types that have been genetically profiled -adenoid cystic carcinomas and polymorphous low-grade adenocarcinomas -which both have a relative paucity of actionable targets (25, 41) . Therefore, routine clinical tumor sequencing in SDCs may yield potentially actionable information. cancer ( Figure 2B-C) (43) . Expression of AR-V7 was confirmed by RT-PCR in 7 of the 8 cases ( Figure   2C ). This confirms data from a prior study identifying AR-V7 in SDC (44) , and additionally demonstrate that in many cases, the ratios of AR-V7 are quite low in comparison to full-length AR. These results suggest that future clinical trials investigating ADT in SDC should incorporate assessment of the presence, and ratios of AR-V7, in tumors before and during/after treatment, and that RNA sequencing is a more sensitive measure than RT-PCR.
Alterations affecting androgen receptor signaling
Forkhead box protein A1 (FOXA1) is a pioneer transcription factor that acts by binding to and exposing chromatin, thereby enabling AR and other hormone receptors to activate transcription of their target genes. In prostate cancer, AR and FOXA1 protein levels correlate with each other, and high FOXA1 levels are associated with poor prognosis and the development of metastasis (45) . In SDC, we also noted a strong correlation between FOXA1 and AR mRNA levels in SDC tumors ( Figure 2D ).
Although functional studies are lacking, clinical data have suggested that FOXA1 mutations may be associated with ADT resistance (46) . Three SDC patients had FOXA1 mutations, which did not appear to affect AR expression levels ( Figure 2D ). Like most FOXA1 mutations found in ADT-resistant prostate cancer (46) , these were all located in the DNA binding domain ( Figure 2E ). To investigate the effect of the FOXA1 mutations on AR activity, we compared AR mRNA levels to a composite estimate of AR signaling, derived from the average expression of 46 canonical genes upregulated by AR (see Methods).
AR signaling correlated with AR expression at both protein and mRNA levels. Interestingly, the tumor with a Q263-C268 FOXA1 deletion showed low AR signaling despite the highest AR expression of all cases ( Figure 2F and G) . This suggests that the Q263-C268 deletion represses AR signaling, although these data are preliminary and the hypothesis requires additional confirmation. Nevertheless, the presence of FOXA1 mutations in SDC is likely to have significant implications as ADT is investigated in SDC.
Research. We also detected two missense mutations, one frameshift insertion and one amplification of the fatty acid synthase (FASN) gene. Overexpression of FASN is prevalent in several tumor types and been proposed as a potential ADT resistance mechanism in prostate cancer (47) , although mechanistic data remain lacking.
In our study, 4 patients with AR-positive tumors and recurrent disease received ADT treatment with or without chemotherapy. Of these patients, 3 developed progression of disease and 1 currently remains on therapy with stable disease after 17 months.
SDC resembles molecular apocrine breast cancer
Morphologically, SDC resembles invasive ductal carcinoma of the breast, and the two diseases share some immunohistochemical features such as AR and ERBB2 expression, which are seen in 58-87% and 20% of breast cancers, respectively (6, 7, 48) . Thus it is possible that SDC and breast cancer may be molecularly similar. However, this has not been previously investigated at the scale of global gene expression.
We performed unsupervised hierarchial clustering based on gene expression data from RNA sequencing in the 16 cases of SDC and 591 breast cancers sequenced by TCGA (22) . Despite arising from a different organ, the SDC tumors did not cluster separately from the breast cancers. Instead, they clustered together with basal-like and HER2-enriched breast tumors, and separately from Luminal A, Luminal B and normal-like breast tumors ( Figure 3A) . As has been suggested based on IHC data (4, 6), we found that SDCs could be divided into three groups based on AR and ERBB2 gene expression. Four tumors had low AR and ERBB2 levels, 8 tumors had high AR and low ERBB2, and 4 tumors had high AR and ERBB2 ( Figure 3B ). Interestingly, 3 of 4 SDCs with low AR and ERBB2 expression clustered with basal-like breast cancers, whereas AR-high cases, regardless of ERBB2 status, predominately clustered with ERBB2-enriched breast cancers ( Figure 3C ). These findings indicate that SDC shows a distinct similarity to breast cancer not only by histology and immunohistochemistry, but also by global gene expression patterns. 
To determine which breast cancer subtype SDC is closest to based on molecular profile, we then performed consensus clustering of the SDCs and 109 basal-like breast tumors from TCGA according to methods described by Lehmann et al. (49) . Similar to that study, we detected an optimal number of 7 clusters (Supplementary Figure 8) . All SDC cases were classified together with a subset of the breast tumors forming cluster 1 ( Figure 4A ). To explore the nature of this cluster, we performed gene set enrichment analysis (GSEA), using gene sets specific for different subtypes of breast cancer as defined by -16-0637 SDCs are aggressive salivary cancers, with no highly active systemic therapy, and no predictive biomarkers. The majority of tumors are ultimately treatment-resistant and lethal. Our results show that the majority (61%) of SDCs have alterations with published clinical evidence supporting specific targeted therapies. In the emerging era of precision oncology and biomarker-defined basket studies, these data suggest that routine clinical tumor sequencing for this disease is likely to be of high clinical value.
Our results suggest that ADT could be investigated in the majority of SDCs, and ERBB2 inhibition in a subset of the patients. We found evidence supporting several potential mechanisms of resistance to these drugs, such as AR-V7 expression and FOXA1 mutations in AR-positive tumors, and PI3K-AKT pathway alterations in cases with ERBB2 amplification. It will be important to assess these genetic and expressionbased biomarkers in correlative analyses for patients enrolled on ADT or ERBB2 inhibitor trials.
These data also define the diverse molecular landscape of SDC. For example, we describe the first occurrence of the ETV6-NTRK3 fusion gene in a tumor with histologic features and IHC profile typical of SDC.
Finally, we show that the gene expression pattern of SDC is highly similar to that of molecular apocrine breast carcinoma. This has long been speculated based on similarities in IHC, but has not heretofore been confirmed at the level of genome-wide data. It is likely that parallel clinical investigation of ADT and other treatments in apocrine breast cancer will generate useful data and hypotheses for SDC trials, which are currently constrained by the rarity of this cancer. MLH3  MSH5  TP53  BRAF  HRAS  NF1  EGFR   FGFR1  KDR  RET  AKT1  DOCK7  MTOR  PIK3CA  RPTOR  FASN  FOXA1   KDMA6  KMT2B  KMT2C  KMT2E  NSD1  SMARCA4  ABL1  CDH1  SF3B1  SMAD4  ETV6- N o e v id e n c e P r e c li n ic a l e v id e n c e C li n ic a l e v id e n c e in a n o t h e r in d ic a t io n C li n ic a l e v id e n c e in SDC14  SDC10  SDC12  SDC1  SDC8  SDC3  SDC5  SDC11  SDC4  SDC9  SDC16  SDC7  SDC13  SDC15  SDC6 
